Immunoglobulin-derived synthetic native and heteroclitic peptides
| Name . | Position . | Sequence . | Parker score . | Rammensee score . | FI . | CTLs induced/ donors tested . |
|---|---|---|---|---|---|---|
| FR9 | FR3 | TLFLQMNSL | 181 | 24 | 0.2 | 3/6 |
| FR9H | KLFLQMNSL | 636 | 25 | 0.2 | 1/1 | |
| FR13 | FR2 | CVLLCEIWV | 123 | 16 | Not available | Not tested |
| FR13H | KVLLCEIWV | 1935 | 23 | 0.6 | 2/2 | |
| FR15 | FR3 | NQFSLKLSSV | 60 | 17 | 0.9 | 1/6 |
| FR15H | NQFSLKLSSV | 591 | 27 | 2.0 | 1/3 | |
| FR16 | FR3 | SLQPEDFAT | 43 | 19 | 1.3 | 3/7 |
| FR16H | κ | SLQPEDFAV | 403 | 25 | 2.8 | 2/4 |
| FR17 | FR3 | YLQMNSLRA | 22 | 17 | 0.3 | 2/7 |
| FR17H | YLQMNSLRV | 320 | 23 | 1.8 | 3/3 | |
| FR18 | FR2 | QAPGKGLEWV | 6 | 20 | 0.4 | 0/5 |
| FR18H | QLPGKGLEWV | 431 | 26 | 1.3 | 2/2 | |
| FR21 | FR2 | APGKGLEWV | 3 | 18 | 0.1 | 2/6 |
| FR21H | ALGKGLEWV | 431 | 28 | 2.7 | 2/3 | |
| FR23 | FR3 | STAYMELSSL | 1 | 23 | 0.6 | 2/6 |
| FR23H | SLAYMELSSL | 49 | 29 | 1.4 | 2/3 | |
| FR24 | FR2 | FPGKGLVWV | 26 | 19 | 0.2 | 0/8 |
| FR24H | FLGKGLVWV | 4047 | 29 | 2.3 | 1/4 | |
| FR25 | FR3 | AVYLQMNSL | 14 | 20 | 0.1 | 0/8 |
| FR25H | AVYLQMNSV | 512 | 26 | 2.4 | 1/4 | |
| FR26 | FR3 | TLYLQMDNL | 77 | 21 | 0.6 | 0/5 |
| FR26H | KLYLQMDNV | 878 | 22 | 1.3 | 2/4 | |
| FR27 | FR3 | SVIAADTAV | 6 | 19 | 0.1 | 0/2 |
| FR27H | KVIAADTAV | 243 | 24 | 0.9 | 1/2 | |
| FR28 | FR3 | NQFTLKLTSV | 60 | 17 | 0.5 | 0/2 |
| FR28H | NLFTLKLTSV | 2071 | 28 | 1 | 0/2 | |
| FR29 | FR3 | NQFSLKLSSV | 60 | 17 | 0.3 | 0/2 |
| FR29H | KLFSLKLSSV | 2071 | 28 | 0.8 | 0/2 | |
| FR30 | FR3 | TLYLQMNSL | 157 | 24 | 0.1 | 0/2 |
| FR30H | KLYLQMNSV | 1792 | 25 | 0.5 | 1/2 | |
| FR31 | FR3 | AVYYCARDLV | 10 | 16 | 0.7 | 0/2 |
| FR31H | KVYYCARDLV | 382 | 21 | 0.09 | 1/2 | |
| CDR16 | CDRI | IVSDNCMSWV | 537 | 17 | 0.5 | 1/5 |
| CDR16H | ILSDNCMSWV | 6132 | 23 | 1.8 | 1/4 | |
| CDR17 | CDRII | KGLEWISGYI | 6 | 17 | 0.6 | 0/2 |
| CDR17H | KLLEWISGYV | 6072 | 29 | 1.3 | 1/2 | |
| MAGE | aa 271 | FLWGPRALV | 2655 | 27 | 2.6 | 12/12 |
| Name . | Position . | Sequence . | Parker score . | Rammensee score . | FI . | CTLs induced/ donors tested . |
|---|---|---|---|---|---|---|
| FR9 | FR3 | TLFLQMNSL | 181 | 24 | 0.2 | 3/6 |
| FR9H | KLFLQMNSL | 636 | 25 | 0.2 | 1/1 | |
| FR13 | FR2 | CVLLCEIWV | 123 | 16 | Not available | Not tested |
| FR13H | KVLLCEIWV | 1935 | 23 | 0.6 | 2/2 | |
| FR15 | FR3 | NQFSLKLSSV | 60 | 17 | 0.9 | 1/6 |
| FR15H | NQFSLKLSSV | 591 | 27 | 2.0 | 1/3 | |
| FR16 | FR3 | SLQPEDFAT | 43 | 19 | 1.3 | 3/7 |
| FR16H | κ | SLQPEDFAV | 403 | 25 | 2.8 | 2/4 |
| FR17 | FR3 | YLQMNSLRA | 22 | 17 | 0.3 | 2/7 |
| FR17H | YLQMNSLRV | 320 | 23 | 1.8 | 3/3 | |
| FR18 | FR2 | QAPGKGLEWV | 6 | 20 | 0.4 | 0/5 |
| FR18H | QLPGKGLEWV | 431 | 26 | 1.3 | 2/2 | |
| FR21 | FR2 | APGKGLEWV | 3 | 18 | 0.1 | 2/6 |
| FR21H | ALGKGLEWV | 431 | 28 | 2.7 | 2/3 | |
| FR23 | FR3 | STAYMELSSL | 1 | 23 | 0.6 | 2/6 |
| FR23H | SLAYMELSSL | 49 | 29 | 1.4 | 2/3 | |
| FR24 | FR2 | FPGKGLVWV | 26 | 19 | 0.2 | 0/8 |
| FR24H | FLGKGLVWV | 4047 | 29 | 2.3 | 1/4 | |
| FR25 | FR3 | AVYLQMNSL | 14 | 20 | 0.1 | 0/8 |
| FR25H | AVYLQMNSV | 512 | 26 | 2.4 | 1/4 | |
| FR26 | FR3 | TLYLQMDNL | 77 | 21 | 0.6 | 0/5 |
| FR26H | KLYLQMDNV | 878 | 22 | 1.3 | 2/4 | |
| FR27 | FR3 | SVIAADTAV | 6 | 19 | 0.1 | 0/2 |
| FR27H | KVIAADTAV | 243 | 24 | 0.9 | 1/2 | |
| FR28 | FR3 | NQFTLKLTSV | 60 | 17 | 0.5 | 0/2 |
| FR28H | NLFTLKLTSV | 2071 | 28 | 1 | 0/2 | |
| FR29 | FR3 | NQFSLKLSSV | 60 | 17 | 0.3 | 0/2 |
| FR29H | KLFSLKLSSV | 2071 | 28 | 0.8 | 0/2 | |
| FR30 | FR3 | TLYLQMNSL | 157 | 24 | 0.1 | 0/2 |
| FR30H | KLYLQMNSV | 1792 | 25 | 0.5 | 1/2 | |
| FR31 | FR3 | AVYYCARDLV | 10 | 16 | 0.7 | 0/2 |
| FR31H | KVYYCARDLV | 382 | 21 | 0.09 | 1/2 | |
| CDR16 | CDRI | IVSDNCMSWV | 537 | 17 | 0.5 | 1/5 |
| CDR16H | ILSDNCMSWV | 6132 | 23 | 1.8 | 1/4 | |
| CDR17 | CDRII | KGLEWISGYI | 6 | 17 | 0.6 | 0/2 |
| CDR17H | KLLEWISGYV | 6072 | 29 | 1.3 | 1/2 | |
| MAGE | aa 271 | FLWGPRALV | 2655 | 27 | 2.6 | 12/12 |
Shown are the name, position, sequence (single-letter abbreviations for amino acids) with heteroclitic changes (in boldface and underlined), calculated score of predicted half-life (Parker et al29 and Rammensee et al31) in arbitrary units, fluorescence index (FI) of binding to human HLA-A*0201, and number of cytotoxic T-lymphocyte (CTL) lines generated from healthy donors that elicited specific killing of peptide-pulsed, CD40-activated B cells for all peptides tested.
FR indicates framework region; CDR, complementarity-determining region; and MAGE, melanoma antigen.